Background
==========

Methionine (Met) is a sulfur-containing amino acid that is particularly susceptible to oxidation by reactive oxygen species (ROS). Methionine oxidation results in the formation of a mixture of two diastereomeric forms of methionine sulfoxide (MetO), which can be reduced back to Met by methionine sulfoxide reductases (Msrs) A (MsrA) and B (MsrB). These enzymes play an important role in protection of proteins against oxidative stress and have been implicated in regulation of the aging process. Insufficient repair of oxidized Met by these enzymes may alter protein structure and cause protein aggregation and/or loss of function, accelerating age-associated diseases \[[@B1]-[@B10]\]. Higher levels of MetO and carbonyl groups in proteins were found in the brains of Alzheimer's disease patients based on postmortem pathology analyses \[[@B11]\]. The reversible oxidation of Met residues may also modulate protein-protein interactions and participate in intracellular signaling \[[@B12],[@B13]\]. Thus, identification of proteins most susceptible to Met oxidation may help better understand age-associated diseases and signaling pathways.

Conventional assays for detection of MetO and monitoring its reduction rely on HPLC and mass-spectrometry procedures \[[@B14],[@B15]\]. In addition, there have been several reports on the use of antibodies specific for certain MetO-containing peptides to detect oxidation of these peptides \[[@B13],[@B16]\]. There is also a report on the use of antibodies specific for oxidized plant protein DZS18, enriched for Met residues, to detect MetO in cellular proteins \[[@B17]\]. While providing new tools and approaches, these studies, as well as our own previous analyses, have not yet resulted in specific identification of MetO in proteins under physiological conditions.

In this regard, an important approach in developing tools for MetO research is the use of Met-rich proteins (MRPs). Previously, we identified and characterized three such proteins and developed methods to monitor their Met oxidation and MetO reduction by SDS-PAGE and immunoblot assays \[[@B18]\]. In the current work, we describe four new MRPs, which in addition to Met enrichment have an added benefit of being deficient in cysteine (Cys), another sulfur-containing amino acid highly susceptible to oxidation. We report characterization of these proteins and antibodies generated against MetO forms of these proteins. We further used these MRPs to examine various features of Met oxidation and repair in proteins.

Methods
=======

*Materials*. Genomic DNA of *Idiomarina loihiensis* L2TR and *Saccharophagus degradans* 2--40 was kindly provided by Dr. Maqsudul Alam and Dr. Steven Hutcheson, respectively. *Pseudomonas putida* W619 cells \[[@B19]\] were kindly provided by Dr. Daniel van der Lelie. Expression constructs for MRP1 and MRP2, mouse MsrA, mouse MsrB2, and MsrA-MsrB fusion protein (MsrBA) were previously described \[[@B18],[@B20],[@B21]\]. Msr null strains were also described previously \[[@B22]\]. Reagents used in this work were of the highest grade possible.

Computational identification of MRPs
------------------------------------

In an initial step of the search procedure, we adopted a strategy similar to that previously used for identification of MRPs \[[@B18]\]. Specifically, using in-house scripts, each protein in the NCBI non-redundant protein dataset (downloaded from <ftp://ftp.ncbi.nih.gov>) was scanned for Met content and protein length. Sequences with Met content above 20%, length more than 50 amino acids and pronounced secondary structures, were selected. Subsequently, Cys content was analyzed for each MRP. Proteins with more than 20% Met and low number of Cys (or lacking Cys) were further considered. The MRP candidates deemed more likely to be soluble were then selected by manual analysis for further experimental studies.

Cloning, expression, purification and mass spectrometry analyses of MRPs
------------------------------------------------------------------------

Sequences coding for MRP4 (from codon 23 to stop codon), MRP5 (from codon 21 to stop codon), and MRP6 (from codon 21 to stop codon) were PCR-amplified from the corresponding genomic DNA. MRP3 coding region starting from amino acid 22 was amplified from mRNA isolated from *Zea mays*. MRP7 coding region was amplified from mouse liver mRNA. PCR products of MRP3-MRP6 were sequenced, digested with either NdeI and NotI or Nhe1 and Not1 (for MRP4, MRP6) and cloned into pET21b vector to generate the constructs coding for proteins with His-tags at the C-terminus. The PCR product of MRP7 was cloned into Nde1/Not1 sites of pET28a+ to generate the construct coding a protein with a His-tag at both N- and C-terminus. Soluble (MRP1-MRP2, MRP4-MRP7) and insoluble (MRP3) recombinant MRPs were purified on Talon columns following expression in *E. coli* using a previous procedure \[[@B18]\]. Mass-spectrometry analyses of MRPs were also carried out as described previously \[[@B18]\].

Oxidation of MRPs by H~2~O~2~
-----------------------------

Purified MRPs were subjected to controlled oxidation by various concentrations of H~2~O~2~ or other indicated oxidants, wherein oxidation was monitored by the mobility of proteins on SDS-PAGE gels. To verify that the shift in mobility was due to Met oxidation, the oxidized proteins were subjected to reduction with Msrs in the presence of DTT or thioredoxin (Trx) as described below.

Preparation of oxidized MRPs to generate antibodies specific for oxidized MRPs
------------------------------------------------------------------------------

Purified MRP3-MRP7 were oxidized with 10--50 mM H~2~O~2~ at room temperature for 12 h, the oxidized proteins subjected to SDS-PAGE analysis to determine the extent of oxidation, and ESI-MS analyses were carried out to measure the number of oxidized Met residues. The conditions that resulted in oxidation of all Met in proteins (these were slightly different for various MRPs) were used to prepare oxidized MRPs at large scale for immunization. Rabbit polyclonal antibodies were produced by Covance, Inc.

Enrichment of antibodies specific for oxidized MRPs
---------------------------------------------------

Affinity columns containing reduced or oxidized MRP were used to enrich polyclonal antibodies specific for oxidized MRPs. To prepare an MRP affinity column, 2--6 mg of a reduced or oxidized MRP (the same preparation as that used for immunization) were coupled to NHS-activated Sepharose (GE Life Science, Piscataway, NJ) according to manufacturer's instructions. The antibody purification procedure included the following two alternatives: (i) One-step enrichment. The antisera were first purified on a protein G Sepharose column (GE Life Science, Piscataway, NJ), and then the resulting IgG fraction (10--20 mg) was dialyzed against PBS and further applied to a column containing a reduced MRP at room temperature for 2 h, with shaking. The unbound fraction was collected and the Sepharose column was washed with 5 volumes of PBS, followed by elution of the bound antibodies. The unbound and wash fractions were re-purified on the column with reduced MRP twice using the same procedure. The final unbound and wash fractions were used for immunoblot analyses to examine specificity of the resulting antibodies. (ii) Two-step enrichment. The final unbound and wash fractions obtained by the procedure described above were further purified on the affinity columns containing oxidized MRPs and the bound antibodies were eluted and used for further immunoblot analyses.

Msr activity assays using MRPs
------------------------------

The DDT-dependent assay was carried out as following: 2--4 μg of an oxidized MRP were incubated with 5 mM DTT and 0.5-4 μM Msrs at 37°C for 2 h, and the reaction mixture was mixed with SDS-PAGE sample buffer and subjected to SDS-PAGE analysis. The Trx-dependent assay was as follows: 2--4 μg of an oxidized MRP were incubated with 6.8 μM Trx, 0.2 μM NADPH, and 0.4 μM Trx reductase at 37°C for 2 h, and the reaction was subjected to SDS-PAGE analysis.

Results
=======

Computational identification of MRPs
------------------------------------

The three first-generation MRPs characterized in our previous work \[[@B18]\] contained Cys residues, which either interfered with some redox assays that targeted Met oxidation and MetO reduction, or required an additional blocking step prior to MetO analyses. To address this issue, we conducted a computational search for MRPs that had few or no Cys residues. An analysis of the NCBI non-redundant protein database, which also included ORFs encoded in completely sequenced genomes, revealed approximately 170 sequences with more than 20% Met content (10 fold higher Met content than expected by chance based on Met content of proteins in the NCBI database), which were present in organisms ranging from bacteria to mammals. These proteins were further analyzed for Cys content and secondary structure composition. We selected proteins expected to be soluble based on their predicted secondary structure or modeled 3D structures, and which in addition showed a maximal Met content and few or no Cys residues. The final set of MRPs selected based on this procedure had 21-33% Met and 0-2% Cys (Table [1](#T1){ref-type="table"}).

###### 

MRPs characterized in this study

  **Protein**                             **Organism**                      **Accession number**   **\# of Met residues \***   **% of Met**   **\# of Cys residues\***   **% of Cys**
  --------------------------------------- --------------------------------- ---------------------- --------------------------- -------------- -------------------------- --------------
  Hypothetical protein (FeNos, MRP1)      *Nostoc* sp. PCC 73102            ZP_00345849            41 (38)                     33             15 (15)                    12
  Hypothetical protein (LegP, MRP2)       *Legionella pneumophila*          YP_095088              37 (35)                     25             2 (1)                      1
  Delta zein structural18 (DZS18, MRP3)   *Zea mays*                        NP_001105054           50 (49)                     24             4 (3)                      2
  Hypothetical protein (MRP4)             *Pseudomonas putida* W619         YP_001746901           32 (31)                     21             1 (0)                      1
  Hypothetical protein (MRP5)             *Idiomarina loihiensis* L2TR      YP_155605              32 (31)                     22             0 (0)                      0
  Hypothetical protein (MRP6)             *Saccharophagus degradans* 2-40   YP_527410              36 (35)                     25             0 (0)                      0
  Calmodulin (MRP7)                       *Mus musculus*                    NP_031615              10 (12)                     7              0 (0)                      0

\* Numbers correspond to the number of indicated amino acids encoded in the ORF, and the numbers in brackets correspond to the amino acid residues present in recombinant MRPs (difference is due to removal of signal peptides).

Preparation of recombinant MRPs
-------------------------------

For experimental analyses of MRPs, we selected two proteins from a previous study, including FeNos (herein designated MRP1) from *Nostoc sp*, and LegP (herein designated MRP2) from *Legionella.* Recombinant MRP1 contained 15 Cys residues and MRP2 a single Cys residue. Both proteins were prepared as His-tag forms and found to be soluble. The new MRPs included DZS18 (here designated MRP3), a previously characterized storage protein from *Zea mays*\[[@B17]\], and three hypothetical proteins from *Pseudomonas putida* W619 (designated MRP4), *Idiomarina loihiensis* L2TR (MRP5), and *Saccharophagus degradans* 2--40 (MRP6). In addition, we analyzed calmodulin, a calcium sensor protein that contains regulatory Met residues \[[@B23]\]. Mouse calmodulin (designated MRP7) had 7% Met, so even though its Met content was below 20%, it was much higher than the average Met content of proteins (\~2%). The four expressed proteins, MRP3-MRP6, were prepared in the forms that lacked predicted N-terminal signal peptides (20--22 amino acids). With regard to Cys content, MRP3 had 3 Cys residues, whereas all other new MRPs lacked Cys. These proteins could be expressed and isolated using standard procedures with a high degree of purity (Figure [1](#F1){ref-type="fig"}).

![**SDS-PAGE analysis of recombinant MRPs.** His-tagged recombinant MRPs (MRP1 to MRP7) were identified through a computational procedure, cloned, expressed in *E. coli* BL21 cells, purified on Talon resin, and the purified proteins subjected to SDS-PAGE analysis and visualized by Coomassie Blue staining. Lanes 1 to 7 correspond to MRP1 to MRP7, respectively.](1471-2091-13-21-1){#F1}

MRP-based analyses of Met oxidation and MetO reduction by SDS-PAGE
------------------------------------------------------------------

We previously demonstrated that oxidation of Met residues in the first-generation, Cys-containing MRPs could be monitored by protein mobility shift using SDS-PAGE gels, and that MetO-containing MRPs migrated slower than the corresponding reduced proteins \[[@B18]\]. To further examine the utility of SDS-PAGE analysis for monitoring MRP oxidation, we oxidized 60 μM MRP1 with different concentrations of H~2~O~2~ and for various periods of time. The as-isolated and oxidized forms of MRP1 were resolved on 10% SDS-PAGE gels and visualized by Coomassie blue staining (Figure [2](#F2){ref-type="fig"}A). Migration of MRP1 only slightly changed when the protein was incubated with 1 mM or less H~2~O~2~ for 7--12 h, whereas it migrated significantly slower at higher H~2~O~2~ concentrations. Moreover, mobility of MRP1 proportionally decreased with the increase in H~2~O~2~ levels and time of treatment; the maximal oxidation was achieved by treating the protein with 10 mM H~2~O~2~ for 12 h.

![**Analyses of Met oxidation and MetO reduction in MRPs by SDS-PAGE.** (**A**) 60 μM MRP1 was treated with indicated concentrations of H~2~O~2~ for 7 or 12 h, and protein oxidation was monitored by the mobility shift on SDS-PAGE gels, as visualized by Coomassie Blue staining. Open triangles represent increasing treatment time (i.e., 7, 12 h). (**B**) 60 μM MRP5 was oxidized with indicated concentrations of H~2~O~2~ at room temperature for 12 h, and MetO formation was monitored by the mobility shift on SDS-PAGE gels, as visualized by Coomassie Blue staining. (**C**) Mass-spectrometry analysis of reduced MRP5 and the protein oxidized by 10 mM H~2~O~2~ at room temperature for 12 h. Theoretical and observed masses are shown.](1471-2091-13-21-2){#F2}

We further examined Met oxidation by H~2~O~2~ in other MRPs by in-gel assays as well as by mass spectrometry. Met residues could be fully oxidized in MRP2, MRP4, MRP5, and MRP6 when 60 μM proteins were treated with 10 mM H~2~O~2~ at room temperature for 12 h; however, 20 mM and 50 mM H~2~O~2~ was required to fully oxidize MRP3 and MRP7, respectively. These data suggest that structural and sequence context in which Met is present may influence efficiency of its oxidation. Figure [2](#F2){ref-type="fig"}B shows oxidation of MRP5 as monitored by in-gel assays, and Figure [2](#F2){ref-type="fig"}C, for comparison, oxidation of the same protein as monitored by mass spectrometry. Following 10 mM H~2~O~2~ treatment, the observed mass of MRP5 increased to that corresponding to the mass of the fully oxidized MRP containing 31 MetO. Thus, Met oxidation in MRPs resulted in slower migration of all MRPs on SDS-PAGE gels, indicating that this is a general feature of Met oxidation.

Met residues are sensitive to two-electron oxidants
---------------------------------------------------

To examine sensitivity of Met residues to different oxidants, we treated 20 μM MRP5 with H~2~O~2~ or NaOCl, which are two-electron oxidants, and with CuSO~4~ or FeCl~3~, which are one-electron oxidants. Treatment of MRP5 for 1 h at 37°C oxidized approximately 50% Met residues when 10 mM H~2~O~2~ was used, and full oxidation was achieved upon treatment with 50 mM H~2~O~2~. Further increase in H~2~O~2~ levels to 100 mM did not change MRP5 mobility on SDS-PAG gels, but also did not lead to significant protein degradation (Figure [3](#F3){ref-type="fig"}A). 1 mM NaOCl could oxidize this MRP to the same extent as that caused by the treatment with 10 mM H~2~O~2~; however the amount of oxidized MRP5 decreased when the protein was treated with 5 mM NaOCl, and the protein was essentially undetectable after treatment with 10 mM NaOCl (Figure [3](#F3){ref-type="fig"}A). Thus, compared with H~2~O~2~, NaOCl is a stronger oxidant of Met in proteins, and at higher concentrations it can break peptide bonds. The mobility of MRP5 on SDS-PAGE gels did not change when the protein was treated with CuSO~4~ or FeCl~3~, suggesting that they are inefficient Met oxidants (Figure [3](#F3){ref-type="fig"}B).

![**Oxidation of Met in MRPs by various oxidants.** 20 μM MRP5 was oxidized with the indicated concentrations of (**A**) hydrogen peroxide (H~2~O~2~) or sodium hypochlorite (NaOCl) at 37°C for 1 h; (**B**) CuSO~4~ or FeCl~3~ at 37°C for 2 h, and then subjected to SDS-PAGE analysis.](1471-2091-13-21-3){#F3}

Analyses of Msr activities by in-gel assays using MRPs as substrates
--------------------------------------------------------------------

We further subjected oxidized MRPs to treatment with Msr enzymes (Figure [4](#F4){ref-type="fig"}). MsrA, MsrB or the natural fusion protein containing both MsrA and MsrB domains, MsrBA, could efficiently reduce MetO in MRPs. For example, 4 μg MRP1 required 0.5 μM MsrA or MsrB for 50% reduction (Figure [4](#F4){ref-type="fig"}A,B) and could be completely reduced by either MsrBA or a combination of MsrA and MsrB (Figure [4](#F4){ref-type="fig"}B,C). We also utilized the same assay to examine the Trx-dependent Msr activity and found that Msrs could efficiently use Trx to reduce MRPs. For comparison, the reduction of Cys-free MRPs by Msrs was examined by treatment of oxidized MRP5 with Msrs. Interestingly, besides a complete reduction of oxidized MRP5 by Msrs both in DTT- and Trx-dependent assays, this MRP required less NADPH compared with the reduction of MRP1, which contained 15 Cys. The quantitative reduction of MRPs suggested that MsrA and MsrB could target all MetO in these proteins, although probably with different efficiency.

![**Msr activity assays by following MRP electrophoretic mobility shift on SDS-PAGE gels.** 4 μg of as-isolated (lane 1) or oxidized (lanes 2 to 12) MRP1 were incubated with Msrs and DTT or Trx as described in Materials and Methods, electrophoresed on 10% SDS-PAGE gels and stained with Coomassie Blue. Migration of reduced (R) and oxidized (O) MRP1 is shown by arrows. (**A**) MsrA activity assay. (**B**) MsrB activity assay (lanes 2 to 11) and MsrA plus MsrB activity assay (lane 12). (**C**) MsrBA activity assay. When used separately, MsrA and MsrB partially reduced oxidized Met residues, whereas treatment with MsrBA completely restored mobility of the reduced protein.](1471-2091-13-21-4){#F4}

Antibodies specific for oxidized MRPs
-------------------------------------

To generate antibodies recognizing MetO residues, we optimized large-scale MRP oxidation by following mobility of MRPs on SDS-PAGE gels and carrying out mass spectrometry analyses. Antibodies were prepared against all oxidized MRPs, but, as expected, they were found to recognize both reduced and oxidized forms of these proteins. Therefore, we isolated antibodies on affinity columns containing conjugated reduced MRPs, and the flow-through fractions from these columns were found to be enriched for oxidized MRPs. These antibodies were designated e.g. a-MRP4-OX and a-MRP6-OX, for antibodies enriched for oxidized MRP4 and MRP6, respectively (Figure [5](#F5){ref-type="fig"}A,B). To examine specificity of the enriched antibodies to MRP4, the oxidized MRP4 was immunoblotted with the corresponding antibodies (Figure [5](#F5){ref-type="fig"}C), which was found to only recognize the protein after it was treated with 2 mM or higher concentrations of H~2~O~2~. Subsequent analyses with reduced and oxidized MRP4 revealed that the antibodies could recognize as little as 20 ng oxidized protein (Figure [5](#F5){ref-type="fig"}D), whereas the reduced MRP4 could only be detected when the protein amounts were increased to 4 μg.

![**Immunodetection of MRP in as-isolated and oxidized forms with antibodies enriched for the corresponding oxidized MRPs.** (**A, B**) 2 μg of MRPs (as-isolated and oxidized forms) were resolved on SDS-PAGE gels, transferred onto PVDF membranes, and analyzed by Western blot assays with the antibodies against indicated oxidized MRPs. Top panel: Polyclonal antiserum (non-enriched) used to detect oxidized MRP4 (**A**) or MRP6 (**B**). Middle panel: Polyclonal antiserum against oxidized MRPs was purified on an affinity column containing reduced MRP, and the unbound fraction (designated enriched) was found to be enriched for the antibodies specific for the oxidized MRPs. Bottom panel: protein loading. "R" indicates reduced and "O" indicates oxidized MRPs. (**C**) 2 μg of MRP4 were oxidized with indicated concentrations of H~2~O~2~ for 12 h at room temperature and detected with non-enriched (top panel) or enriched (bottom panel) antibodies for oxidized MRP4 by Western blot analysis. (**D**) Western blot analysis of different amounts of MRP4 oxidized with 10 mM H~2~O~2~ for 12 h at room temperature with non-enriched and enriched antibodies for oxidized MRP4. Triangles represent increasing amounts of MRP loading (0.25, 0.5, 1, 2 and 4 μg). "MRP4-R" indicates the as-isolated MRP4 (lanes 1 to 5), and "MRP4-O" indicates the oxidized MRP4 (lanes 6 to 10).](1471-2091-13-21-5){#F5}

To test if antibodies enriched for certain oxidized MRPs reacted with other oxidized MRPs, the antibodies enriched for oxidized MRP4 and MRP6 were used to probe various MRPs in both oxidized and reduced forms; the enriched a-MRP4-OX antibodies recognized oxidized MRP2, MRP5 and MRP6, but did not interact with any of the reduced MRPs (Figure [6](#F6){ref-type="fig"}A). The enriched antibodies to oxidized MRP6 recognized oxidized MRP1, MRP2, MRP3, MRP4, and were unable to detect reduced MRPs. However, non-enriched antibodies interacted with both reduced and oxidized forms of MRPs (Figure [6](#F6){ref-type="fig"}B). Similarly, non-enriched antibodies to MRP3 detected reduced and oxidized MRP4 and MRP6 (Figure [7](#F7){ref-type="fig"}A). Based on the observed cross reactivity with MRP4, the antibodies to MRP3 were first applied to the affinity column containing reduced MRP4, and the unbound fraction was further fractionated on the column containing oxidized MRP4; this time the bound and eluted fraction was collected. These antibodies specifically recognized oxidized MRP4 generated by treatment with 5 mM (or higher concentration) H~2~O~2~. However, they did not detect reduced MRP4 or the same protein treated with lower H~2~O~2~ concentrations (Figure [7](#F7){ref-type="fig"}B).

![**Antibodies enriched for the oxidized MRPs recognize other oxidized MRPs.** Western blot analysis of as-isolated (MRP-R; R for reduced) and oxidized (MRP-O; O for oxidized) MRPs (MRP1-MRP7) with initial antisera raised against oxidized proteins (top images in each panel) and enriched antibodies (bottom images in each panel). (**A**) Antibodies against oxidized MRP4. (**B**) Antibodies against oxidized MRP6.](1471-2091-13-21-6){#F6}

![**Enrichment of antibodies for certain oxidized MRPs using affinity columns with other MRPs.** (**A**) Western blot analysis of as-isolated and oxidized (10 mM H~2~O~2~, 12 h) MRP4 and MRP6 with antiserum against oxidized MRP3. "R" indicates as-isolated (i.e., reduced) protein, and "O" indicates oxidized protein. (**B**) Polyclonal antiserum against MRP3 was first purified on a protein G column, then fractionated on an affinity column with as-isolated MRP4, and the unbound fraction was further purified on a column with oxidized MRP4. The bound fraction from the latter column was used for detection of MRP4 oxidized under various H~2~O~2~ treatment conditions.](1471-2091-13-21-7){#F7}

Finally, we tested if the resulting antibodies could recognize MetO-containing proteins in yeast extracts. The antibodies made against oxidized MRP3 and further enriched on the MRP4 column (Figure [7](#F7){ref-type="fig"}B) detected a 62 kDa protein band in the lysate of *S. cerevisiae* BY4741 cells treated with H~2~O~2~ as well as in MsrA/MsrB double knockout lysates treated with H~2~O~2~ (Figure [8](#F8){ref-type="fig"}). However, this protein band showed similar intensity regardless of occurrence of Msrs and its intensity did not increase with the increase in peroxide concentration. We interpret these data to mean limited utility of MRP antibodies for detection of MetO in endogenous proteins. We also employed other approaches, but were not able to generate antibodies that generally recognize MetO. This finding is consistent with a recent article that reported that the previously reported MetO antibodies do not recognize MetO in proteins \[[@B24]\].

![**Antibodies enriched for an oxidized MRP detect a candidate oxidized yeast protein.** Lysates of log-phase yeast cells (BY4741 strain), including wild-type (WT) and MsrA/MsrB double knockout (MsrA/B) strains, were treated with H~2~O~2~, and 30 μg proteins were subjected to Western blot analysis with the antibodies raised against MRP3 that were enriched for the oxidized MRP4 as described in Materials and Methods. (**A**) Yeast lysates were incubated with (lanes 2 and 4) or without (lanes 1 and 3) 100 mM H~2~O~2~ for 1 h at 37°C. (**B**) Wild-type (BY4741) lysates were incubated without (lane 1) or with different concentrations of H~2~O~2~ (lanes 2 to 5) for 1 h at 37°C. The triangles represent increasing amounts of H~2~O~2~ in the oxidation reaction (5, 10, 50, or 100 mM).](1471-2091-13-21-8){#F8}

Discussion
==========

In this work, we characterized Met oxidation and MetO reduction in proteins by SDS-PAGE and immunoblot analyses using novel, second-generation MRPs as substrates. We also developed antibodies specific for oxidized MRPs that could recognize other oxidized MRPs. A key feature of new proteins identified and characterized in the current study is that they contained more than 20% Met, while lacking Cys, whose oxidation may interfere with certain redox assays involving Met oxidation. The use of Cys-free MRPs avoids a complication of variable oxidation of sulfur-containing amino acids \[[@B25]-[@B29]\]: in new MRPs proteins, all oxidation events (under relatively mild oxidizing conditions) correspond to Met oxidation.

Whereas previous studies already showed that Met oxidation may result in a decreased mobility of proteins on SDS-PAGE gels, these studies involved a limited number of proteins, and in some cases, no changes in mobility were observed. The use of 7 MRPs, as reported in our study, demonstrates that the decreased mobility on SDS-PAGE gels is a basic property of Met oxidation. Since each of the MRPs has many Met residues, these proteins could be used to monitor Met oxidation and MetO reduction and to assess the degree of Met oxidation at any given point in the assay.

Interestingly, retardation of migration of oxidized MRPs on SDS-PAGE gels was more pronounced than that expected based on the mass difference between reduced and oxidized proteins. For example, a complete oxidation of Met residues in MRP1 increased the protein mass by 0.6 kDa; however, comparison of migration of this protein with protein standards revealed an apparent 6 kDa shift in mobility. Most Met residues in MRPs could be oxidized to MetO by treatment with 10 mM H~2~O~2~ for 12 h at room temperature, and there was an excellent correspondence between mass-spectrometry and SDS-PAGE analyses. Overall, the use of multiple MRPs allows us to state that Met oxidation that results in slower migration of these proteins on SDS-PAGE gels is a general feature of MRPs, and that it is independent of the occurrence of Cys in these proteins.

Although our data suggested that all Met residues could be oxidized by peroxide and targeted for reduction by Msrs, we observed important differences with regard to efficiency of these processes. For example, the use of H~2~O~2~ concentrations above 10 mM typically did not further change MRP migration on SDS-PAGE gels (because all Met were already oxidized at this concentration). However, calmodulin (it contained fewer Met than other MRPs examined in our study) required approximately 50 mM H~2~O~2~ for full oxidation. These data are also consistent with the observations in a previous report \[[@B23]\] and suggest a role of protein structure in protecting Met from oxidation. The sequence context of Met probably also has an effect on Met oxidation in this protein.

The conversion of Met to MetO involves a two-electron oxidation process \[[@B30],[@B31]\]. We further employed MRPs to assess Met oxidation upon treatment with several one- and two-electron oxidants. MRP5 was insensitive to oxidation by CuSO~4~ and FeCl~3~, and the mobility of MRP2 also did not change when it was treated with 25 μM CuCl~2~ and 25 mM ascorbate for 1 h. With regard to two-electron oxidants, H~2~O~2~ being a milder oxidant was more specific than NaOCl in oxidizing Met, whereas a NaOCl oxidized Met at lower concentrations. NaOCl generates HOCl, which is a strong microbicidal agent, capable of killing bacteria, fungi and viruses, and it can modify various residues in proteins, especially Cys, Met, Trp, and Tyr \[[@B32],[@B33]\]. Protein carbonyls can subsequently be generated from chloramines via the loss of HCl and hydrolysis of the amine \[[@B34]\]. We found that at the ratio of NaOCl to MRP 50:1, most Met residues in MRP5 were oxidized. However, when the ratio increased to 250 fold, the amount of MRP5 decreased due to protein degradation. Thus, MRPs are a convenient tool for examining specificity and efficiency of Met oxidation in proteins.

Another application of MRPs is the use of these proteins as substrates in Msr activity assays. We previously found that oxidized MRPs can be reduced by Msrs in a DTT-dependent assay. In the current work, we utilized Trx-dependent reactions involving MsrA, MsrB and a fusion protein MsrBA and found that this assay is equally amenable to the analysis of MetO reduction in MRPs.

Protein state- and modification-specific antibodies, both monoclonal and polyclonal, have been a great instrument in protein analysis, and this especially applies to phosphorylation state-specific antibodies \[[@B35]\]. These reagents opened many exciting opportunities in signaling and regulation studies as well as in diagnostic pathology. Since MetO chemically differs from Met, an attractive possibility is to develop antibodies specific for MetO-containing proteins. However, previous antibodies that recognize MetO have been limited to certain MetO-containing peptides \[[@B13],[@B16]\]. One difficulty in preparing MetO-specific antibodies is that MetO residues in the antigen may be reduced back to Met in the immunized animals. Among antibodies generated against the seven MRPs examined in the current study, we found that the original antisera against MRP3, MRP4 and MRP6 could be enriched for fractions specific for their respective MetO-containing forms by trapping the antibodies that bind the reduced forms of MRPs. We further purified the antibodies on the columns containing other crosslinked oxidized MRPs. The resulting antibodies recognized other MetO-containing proteins.

We tested a potential application of detecting MetO residues in proteins with the antibodies against various MRPs. MRP3 antibodies enriched on the resin with the oxidized MRP4 could recognize a 62 kDa protein band in yeast lysates treated with H~2~O~2~. Since this protein was weakly detected by the same batch of antibodies in the sample not treated with H~2~O~2~, we reasoned that it is sensitive to oxidation. Previously developed antibodies against MRP3 \[[@B17]\] also detected a protein (estimated 55 kDa) in yeast MsrA null cells treated with H~2~O~2~. However, in our hands, this band was not regulated by MsrA/MsrB status and was not increased by treatment with higher concentration of peroxide. More generally, none of the antibodies we developed were able to generally recognize MetO in proteins. This is also consistent with a recent report \[[@B24]\].

Conclusions
===========

MRPs represent a convenient tool to study Met oxidation and MetO reduction. These proteins and antibodies against them could be used in a variety of applications, several of which are highlighted in our study. MetO can be formed under physiological conditions in cells, but due to low abundance of Met residues and their random oxidation, the analyses of Met oxidation and MetO reduction have been difficult. With the second-generation MRP tools, some of the outstanding questions in Met oxidation and MetO reduction processes can be addressed.
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